Delivery Order SPE2DB24D2109-SPE2DB26FHVUP
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, valued at $1,214.32 with a firm fixed price. The contract, which was competitively awarded without a set-aside designation, has an ultimate completion date of August 14, 2025, and represents a child order under AmerisourceBergen's broader pharmaceutical supply relationship with DLA. The place of performance is listed as the vendor's location in Conshohocken,...
- The Defense Logistics Agency awarded a $5,141.32 delivery order (Contract No. 4569811046) to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injectors, with an ultimate completion date of October 24, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply agreement with DLA. The product will be delivered to AmerisourceBergen's corporate headquarters in...
- The Defense Logistics Agency awarded a $22,429.36 delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with an ultimate completion date of September 17, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The product will be supplied to the place of performance in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a $27,880.54 delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injectors, with an ultimate completion date of September 5, 2025. This non-competitive delivery order represents a firm fixed-price purchase under the company's existing contract vehicle with DLA. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal military and veteran...
- The Defense Logistics Agency awarded a delivery order valued at $11,573.95 to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injectors. This firm fixed-price delivery order, issued on September 12, 2025, with an ultimate completion date of September 15, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The contract was competitively awarded without set-aside designation. AmerisourceBergen, a major...
- The Defense Logistics Agency awarded a $52,128.40 delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with an ultimate completion date of November 3, 2025. The award utilizes firm fixed pricing under a non-set-aside competitive procurement and is classified as a child contract under AmerisourceBergen's larger contract vehicle. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order falls...
- The Defense Logistics Agency awarded a $15,757.00 delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with an ultimate completion date of October 28, 2025. This competitively awarded, firm fixed-price contract was issued without set-aside provisions and is being performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a $36,703.20 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injectors, with an ultimate completion date of September 19, 2025. This non-set-aside competitive award was issued on September 18, 2025, and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The product will be performed at the contractor's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $22,527.18 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors on October 15, 2025, with completion scheduled for October 16, 2025. This firm fixed-price delivery order represents a non-competitive, non-set-aside award issued through the company's existing indefinite delivery contract with DLA Troop Support Medical. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major...
- The Defense Logistics Agency awarded a delivery order valued at $2,270.22 to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injectors, with an ultimate completion date of August 20, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger prime Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December...
- SPE2DB24D2109Indefinite Delivery Contract
- SPE2DB24D2109-SPE2DB26FHVUPDelivery Order
The Defense Logistics Agency awarded a $18,625.21 delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injector medication on October 28, 2025, with an ultimate completion date of October 29, 2025. This non-set-aside contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, with the place of performance located at the company's corporate office in Conshohocken. This delivery order falls under AmerisourceBergen's existing $999,999,999.00 Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, which extends through December 2026 and provides comprehensive pharmaceutical supply support globally for military healthcare programs. The contract vehicle enables the company to supply specialty medications, brand-name and generic drugs, and related medical commodities across multiple therapeutic domains to support the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems. Repatha, an PCSK9 inhibitor used for cholesterol management, represents part of the company's specialized pharmaceutical portfolio delivered through this strategic federal contracting relationship.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $18.6k | 10/28/25 |